Navigation Links
Celsion Announces Date and Time Change for Third Quarter 2010 Financial Results Conference Call to Monday, November 15, 2010
Date:11/10/2010

COLUMBIA, Md., Nov. 10, 2010 /PRNewswire-FirstCall/ -- Celsion Corporation (Nasdaq: CLSN), a late stage biotechnology drug development company that is leveraging its heat sensitive liposomal platform to encapsulate and deliver high concentrations of proven chemotherapeutics, today announced that it has changed  the date and time to discuss third quarter 2010 results due to the Veteran's Day Holiday on November 11, 2010.  The SEC's EDGAR service will not receive, process or accept filings on November 11 because of the Veteran's Day Holiday, and Celsion is rescheduling its third quarter conference call for 3:00 p.m. ET on Monday, November 15, 2010 to enable it to allow for its quarterly report on Form 10-Q for the quarter ended September 30, 2010 and current report on Form 8-K to be filed and furnished to the SEC, respectively, and disseminated to investors in advance of the conference call in compliance with applicable SEC regulations.  To participate in the call, interested parties may dial 1-888-218-8172 (Toll free U.S./Canada) or 1-913-312-9313 (International/Toll) and use Conference ID:  4428936 to register ten minutes before the call is scheduled to begin.  The call will also be broadcast live on the internet at http://www.celsion.com.

The call will be archived for replay on Monday, November 15, 2010 at 6 p.m. ET and will remain available until Monday, November 22, 2010.  The replay can be accessed at 1-877-870-5176 (Toll Free U.S./Canada) or 1-858-384-5517 (International/Toll) using Conference ID:  4428936.  The call will also be available on the Company's website, http://www.celsion.com for 30 days after 5:00 p.m. ET on Monday, November 15, 2010.

About Celsion Corporation Celsion is dedicated to the development and commercialization
'/>"/>

SOURCE Celsion Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Biovista Announces a Drug Repositioning Collaboration With Pfizer
2. ANGIOTECH PHARMACEUTICALS, INC. ANNOUNCES FINANCIAL RESULTS FOR THE THIRD QUARTER ENDED SEPTEMBER 30, 2010
3. Kendle Announces Third Quarter 2010 Results
4. Savara Announces Appointment of Pharmaceutical Veteran to Board of Directors
5. Omthera Pharmaceuticals, Inc. Announces Initiation of the ECLIPSE Trial: Epanova Compared to Lovaza In a Pharmacokinetic Single-dose Evaluation
6. Solutia Announces Sale of Perkalink® Business and Select Primary Accelerators Assets
7. TPC Group Announces Commencement of Dutch Auction Tender Offer to Repurchase for Cash up to $130 Million in Common Stock
8. Alder Biopharmaceuticals Announces That Data From Multiple Studies of ALD518 (BMS945429), an Investigational Antibody Therapeutic in Rheumatoid Arthritis Patients, to be Presented at Annual Meeting of the American College of Rheumatology
9. Hoya Announces Second Quarter Financial Results
10. Metamark Genetics, Inc. Announces New Chief Executive Officer
11. Bolder BioTechnology Announces $1.2 Million in Qualifying Therapeutic Discovery Project Grants
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... The first part of the session on “Best ... Studies” will cover comprehensive clinical support in early phase ... R&D costs and declining industry success in getting products ... collected in early Phase I/IIa study data to make ... development. , Next, the presenters will examine steps to ...
(Date:7/24/2014)... DIEGO , July 24, 2014   ... announced today the appointment of Adam Simpson ... Cypher Genomics provides rapid and comprehensive annotation and ... and clinical reporting. "Cypher,s technology has ... improve healthcare by enhancing diagnostic accuracy, optimizing therapeutic ...
(Date:7/23/2014)... 24, 2014 Lyfebulb, the International Pemphigus ... and NASDAQ OMX First North Premier, ... announced a collaboration to increase awareness of unmet ... an event attended by more than sixty patients, ... a health and wellness company dedicated to serving ...
(Date:7/23/2014)... strides in saving China,s endangered national treasure, the giant ... panda reserves that have been established and three large ... remain in the wild. , Breeding programs in ... by improving genetic diversity, avoid inbreeding and ultimately, introduce ... high-profile programs doing so far? , In a new ...
Breaking Biology Technology:Best Practices for Optimizing Dose Escalation in First in Human Studies, New Webinar August 6th Hosted by Xtalks 2Cypher Genomics Announces the Appointment of Adam Simpson as President and COO to Advance Transformative Genome Interpretation Technology 2Cypher Genomics Announces the Appointment of Adam Simpson as President and COO to Advance Transformative Genome Interpretation Technology 3Innovative Collaboration To Increase Awareness Of Bullous Pemphigoid, A Rare Autoimmune Disease Of The Skin 2Innovative Collaboration To Increase Awareness Of Bullous Pemphigoid, A Rare Autoimmune Disease Of The Skin 3Innovative Collaboration To Increase Awareness Of Bullous Pemphigoid, A Rare Autoimmune Disease Of The Skin 4Innovative Collaboration To Increase Awareness Of Bullous Pemphigoid, A Rare Autoimmune Disease Of The Skin 5
... Nov. 3 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. (TSX:,ONC, ... positive interim,results in its Phase I and Phase ... patients with advanced cancers.,The principal investigator for the ... Cancer Research and The Royal Marsden NHS Foundation ...
... Zentaris Inc.,(NASDAQ: AEZS ; TSX: AEZ), a ... today reported that it has entered the,second stage ... in endometrial,cancer with AEZS-108, a luteinizing hormone-releasing hormone ... the second stage of,patient recruitment was taken following ...
... Neurobiological,Technologies, Inc. (NTI(R)) (Nasdaq: NTII ), ... payment of approximately $2.0 million from Merz,Pharmaceuticals ... the treatment of,moderate-to-severe Alzheimer,s disease. Under an ... payments on certain,sales of Memantine by Merz ...
Cached Biology Technology:Oncolytics Biotech Inc. Collaborators Present Positive Phase I/II Combination REOLYSIN(R) and Paclitaxel/Carboplatin Results at iSBTc Annual Meeting 2Oncolytics Biotech Inc. Collaborators Present Positive Phase I/II Combination REOLYSIN(R) and Paclitaxel/Carboplatin Results at iSBTc Annual Meeting 3Oncolytics Biotech Inc. Collaborators Present Positive Phase I/II Combination REOLYSIN(R) and Paclitaxel/Carboplatin Results at iSBTc Annual Meeting 4AEterna Zentaris Reaches 2nd Stage of Patient Recruitment for Phase 2 Trial in Endometrial Cancer with the Innovative LHRH Receptor Targeted Conjugate, AEZS-108 2AEterna Zentaris Reaches 2nd Stage of Patient Recruitment for Phase 2 Trial in Endometrial Cancer with the Innovative LHRH Receptor Targeted Conjugate, AEZS-108 3AEterna Zentaris Reaches 2nd Stage of Patient Recruitment for Phase 2 Trial in Endometrial Cancer with the Innovative LHRH Receptor Targeted Conjugate, AEZS-108 4AEterna Zentaris Reaches 2nd Stage of Patient Recruitment for Phase 2 Trial in Endometrial Cancer with the Innovative LHRH Receptor Targeted Conjugate, AEZS-108 5
(Date:7/24/2014)... The University of Texas Health Science Center at Houston ... help Harris County residents whose vision problems cannot be ... corrective lenses, many people with low vision can see ... low vision devices, such as telescopes, magnifiers and electronic ... is using the three-year, $164,645 SightFirst grant from the ...
(Date:7/24/2014)... (July 24, 2014) For years, researchers and patients ... nearly any cell type in the bodycould provide insight ... them. Yet progress has been hampered by the inability ... to their human counterparts, in part because human ESCs ... cells. , Now Thorold Theunissen, Benjamin Powell, and Haoyi ...
(Date:7/24/2014)... of fires covered central Africa in mid-July 2014, as ... red hotspots, which indicate areas of increased temperatures, are ... Democratic Republic of the Congo (northeast), and Zambia (southeast). ... and in some areas, especially in the Democratic Republic ... the south. , The fire season is an annual ...
Breaking Biology News(10 mins):UTHealth Dr. Bhavani Iyer awarded low vision grant 2Whitehead Institute researchers create 'naïve' pluripotent human embryonic stem cells 2
... researchers at The Johns Hopkins University School of Medicine reveal ... papers appear in the March issue of The Journal ... opening, many ion channels spontaneously close by inactivation, a process ... channels is important for a variety of biological processes, including ...
... Illinois study touts the benefits of soluble fiberfound in ... the inflammation associated with obesity-related diseases and strengthens the ... immune cellsthey go from being pro-inflammatory, angry cells to ... infection," said Gregory Freund, a professor in the U ...
... NEW ORLEANS, LA. Minerals Management Service (MMS) ... biologists have set sail to learn more about the ... Mexico. The first of the research cruise,s three legs ... is underway. The first and second legs of ...
Cached Biology News:An apple a day? Study shows soluble fiber boosts immune system 2An apple a day? Study shows soluble fiber boosts immune system 3MMS and NOAA scientists study prey of Gulf of Mexico sperm whales 2
Anti-human L-Ficolin, Clone GN4, Monoclonal Antibody...
14-3-3 tau Antibody Shipping Temperature: HOT Storage Temperature: -20C...
Applications: Western blotting Stability: Room temperature, indefinitely ...
... to ARG. Vasopressin The antibody ... Cells are found in the paraventricular ... found throughout the hypothalmus in rat ... Immunogen: Arginine ...
Biology Products: